09/09/14: What are you excited about in the fight against HIV/AIDS?

Back to Top

Contributors:

          
Lawrence Stallworth, Mobile Health Services Specialist, AIDS Taskforce: Greater Cleveland
Kathie Hiers, CEO, AIDS Alabama
Phill Wilson, President and CEO, Black AIDS Institute
Travis Sherer, PA-C, AAHIVS, GLMA
Bill Arnold, Founding Director, CANN

Join The Conversation

07/30/14: We’ve seen great strides to treat arthritis and related diseases. How do we continue to make headway to improve the lives of patients?

Back to Top

Contributors:

            
James P. Sullivan, Ph.D., VP, Pharmaceuticals Discovery, AbbVie
Stephen I. Katz, Director, NIAMS
Amanda Niskar, National Scientific Director, Arthritis Foundation
Christopher F. Smith, CEO, Arthritis Foundation, GLR
Gabriela Lavezzari, AVP, Scientific Affairs , PhRMA
NPF, Partner, Arthritis Contributor

Join The Conversation

07/24/14: What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Back to Top

Contributors:

          
Amy Miller, Executive Vice President, PMC
Raju Kucherlapati, Professor, Department of Genetics, Harvard Medical School
Donna R. Cryer, JD, President & CEO, Global Liver Institute
Randy Burkholder, VP, Policy, PhRMA
Mark Richards, Senior Vice President, Management Supervisor, KRC Research

Join The Conversation

06/17/14: As Americans live longer, how can we tackle aging as a major risk factor for chronic disease?

Back to Top

Contributors:

                
Bob Blancato , Executive Director, NANASP
Cynthia A. Bens, Vice President, Public Policy, Alliance for Aging Research
Dorothy Leone-Glasser, President and CEO, ARxC
Jamesetta Smith, President, Lupus Foundation AR
Paul Downey, President and Chief Executive Officer, Serving Seniors
Thair Phillips, President, RetireSafe
Rob Gundermann, Public Policy Director, ADAW
James Adams, Chairman, Granite State Taxpayers

Join The Conversation

06/11/14: How are patients with chronic conditions who have exchange coverage affected by high out-of-pocket costs for medicines?

Back to Top

Contributors:

                
Margaret Barton-Burke, President, ONS
Angela Ostrom, VP, Public Policy & Advocacy, Epilepsy Foundation
Carl Schmid, Deputy Executive Director, The AIDS Institute
Virginia T. Ladd, President , AARDA
Brian Hujdich, Executive Director, HealthHIV
Bob Blancato , Executive Director, NANASP
Lawrence A. LaMotte, Vice President, Public Policy, Immune Deficiency Foundation
Colon Cancer Alliance, Colon Cancer Alliance, Colon Cancer Alliance

Join The Conversation

06/05/14: We all want to better prevent, treat and cure the many forms of cancer. How close is the collaborative research ecosystem to achieving these goals, and what do we have to do to get there?

Back to Top

Contributors:

      
Josh Schafer, MSc. MBA, Vice President, Oncology Global Marketing Strategy, Astellas Pharmaceuticals
Rafael Amado, Senior Vice President, Oncology R&D, GlaxoSmithKline
Salvatore Alesci , VP, Scientific & Regulatory Affairs, PhRMA

Join The Conversation

05/23/14: How do we promote patient-centered cancer research and care in an era of increasing pressure to control healthcare costs?

Back to Top

Contributors:

        
Marcia Kean, Chairman, Strategic Initiatives, Feinstein Kean Healthcare
Randy Burkholder, VP, Policy, PhRMA
Margaret Foti, CEO, AACR
Gwen Darien , Executive Vice President, CSC

Join The Conversation

05/08/14: What needs to happen to ensure that ‘treatment’ is front and center in America’s ongoing conversation on mental illness?

Back to Top

Contributors:

            
Dr. Bill Chin, EVP, Scientific & Regulatory Affairs, PhRMA
Christine Moutier , Chief Medical Officer, AFSP
Thomas Insel , Director, NIMH
Torsten Madsen , CMO and VP of US Drug Development, Lundbeck
Charles Ingoglia, Senior Vice President, Public Policy and Practice Improvement, The National Council
Allen Doederlein, President, DBSA

Join The Conversation

04/23/14: The annual National Rx Drug Abuse Summit touches on a range of issues including prescription monitoring programs (PDMPs). What are areas of opportunity for strengthening these?

Back to Top

Contributors:

          
Srinivas Nalamachu , Member, Alliance for Patient Access
Ardis Dee Hoven, President, AMA
Thomas MacLellan, Homeland Security & Public Safety Division, NGA
DrugFree.org, Partnership at DrugFree.org, Contributor
Paul Gileno, Founder and President, U.S. Pain Foundation

Join The Conversation

04/15/14: How can we assure that the 340B program provides access to discounted medicines to the indigent and vulnerable patients the program was designed to serve?

Back to Top

Contributors:

              
Eric Hargis , CEO, Colon Cancer Alliance
Texas BioAlliance, Partner, 340B Contributor
Kyle Keeney, Ph.D., KLSC
Michael Hazel, President, Texas Nurse Practitioners
CTD, Partner, 340B Contributor
SWHR, Society for Women’s Health Research, 340B Contributor
The North Carolina State Grange, Contributor, The North Carolina State Grange

Join The Conversation

Pages